Cybertron GmbH

Name ›

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

External ›

Collaborations

Request for ›

Further Collaborations Coriolis Pharma Research GmbH

Fraunhoferstr. 18B 82152 Martinsried Germany Dr Jörg Müller +49-89-417760-111 +49-89-417760-222 Joerg.Mueller@coriolis-pharma.com www.coriolis-pharma.com

I

150+ 2008 Contract research and development

Formulation excellence for biopharmaceuticals, incl.: | Liquid and lyophilised formulations | Lyophilisation process development | Analytical services for biologics | Aggregate & particle analysis | Particle identification | Higher-order structure analysis | Forced-degradation studies | Long-term and in-use stability | Pre-formulation screening | Developability assessment | Supply of TOX-material | Level: R&D, GMP, S1 (BSL1), S2 (BSL2)

Experience with 750+ different molecules gained in 1,500+ projects

Worldwide clients in all stages of product development (early R&D to and beyond market approval). We collaborate with small virtual biotech firms, mid-size pharma-biotech, as well as TOP20 pharma-biotech companies. Approach our experts with your formulation, stability, and analytical challenges. We provide tailor-made, science-driven solutions that align with your development strategy.

Your partner with scientific excellence

Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs including proteins, vaccines, gene- and cell therapy products, viral vectors, nucleic acids, antibodies and related products, peptides, drug delivery systems, and small molecules.

More than 700 customers – from start-ups to Big Pharma – trust the expertise of Coriolis. We develop liquid and lyophilised formulations entirely in-house. For each individual project, our highly skilled scientists develop tailor-made study designs that align with our customers’ drug development strategies. Our formulation services support all phases of drug development from early R&D to and beyond market approval.

Coriolis is specialised in the provision of:

› Formulation development services for liquid and lyophilised products including BSL1 and BSL2 · Pre-formulation and candidate selection · Early stage formulation development · Late phase formulation development · Lyophilisation process development · Lyophilisation cycle optimisation · Robustness, scale-up, and transfer studies › Developability / manufacturability assessment › Support in container closure system selection › In-use stability studies › Stability testing including forced degradation studies › R&D and cGMP-compliant contract analytical services › Orthogonal analysis of subvisible aggregates and particles incl. particle identification › Testing of BSL1 and BSL2 GMO material › Polysorbate analytics › Biosimilarity studies › Supply of preclinical Tox-material › Outstanding scientific expertise

Formulating innovation

By following our mission of “Formulating Innovation”, we combine technologies, knowledge, and experience to add substantial financial value to our customers’ projects by generating IP for your pharmaceutical compound and supporting patent life cycle management in later phases.

Impressive analytical portfolio

Coriolis can draw from a unique portfolio of more than 100 different analytical techniques – performed entirely in-house – to obtain orthogonal and meaningful data. With the in-house lyophilisation development centre, our scientists can obtain time-saving and robust lyophilisation cycles at lab, pilot, and production scale. Dedicated GMP facilities enable us to conduct lot-release analysis and generate supportive data for market approval and allow for tailored “enhanced R&D” level studies. Coriolis – as a trendsetter – provides state-of-the-art as well as promising new and emerging technologies in the field of: › Particle characterisation (from nanometre to visible) › Particle identification › Aggregate analytics › Physico-chemical characterisation of lyophilisates › Surfactant characterisation › Higher order structure analysis › Chemical changes

Your benefits

Our high-quality services are driven by the scientific passion of our experts. You will also benefit from our scientific advisory board that includes some of the most renowned specialists in biopharmaceutical formulation development and particle characterisation: Prof. G. Winter, Prof. W. Friess, Prof. E. Wagner, Prof. G. Kersten, Prof. C. Schöneich, Prof. O. Merkel, Prof. S. Uchiyama, Prof. P. Arosio, and Prof. H. Svilenov. They are actively involved throughout each customer project – if desired – and contribute with independent advice to a successful outcome. The scientific expertise of our project teams is also driven by our internal research unit – composed of post-docs, PhD candidates, and students – who continuously publish exciting articles in high-impact journals.